{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Mychaleckyj JC"],"funding":["NIDDK NIH HHS"],"pagination":["S75-87"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC2917849"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["7(1 Suppl)"],"pubmed_abstract":["<h4>Background</h4>Although human leukocyte antigen (HLA) DQ and DR loci appear to confer the strongest genetic risk for type 1 diabetes, more detailed information is required for other loci within the HLA region to understand causality and stratify additional risk factors. The Type 1 Diabetes Genetics Consortium (T1DGC) study design included high-resolution genotyping of HLA-A, B, C, DRB1, DQ, and DP loci in all affected sibling pair and trio families, and cases and controls, recruited from four networks worldwide, for analysis with clinical phenotypes and immunological markers.<h4>Purpose</h4>In this article, we present the operational strategy of training, classification, reporting, and quality control of HLA genotyping in four laboratories on three continents over nearly 5 years.<h4>Me"],"journal":["Clinical trials (London, England)"],"pubmed_title":["HLA genotyping in the international Type 1 Diabetes Genetics Consortium."],"pmcid":["PMC2917849"],"funding_grant_id":["R01 DK061722","U01 DK062418"],"pubmed_authors":["Pierce JJ","Varney MD","Rappner R","Moonsamy PV","T1DGC","Mychaleckyj JC","Lavant E","Lane JA","Akolkar B","Bonella P","Williams DT","Helmberg W","Erlich HA","Fear AL","Carlson JA","Louey A","Tait BD","Perdue LH","Steffes MW","Sali P","Kim S","Noble JA","Reboussin DM","Boyle S","Post J","Hilner JE"],"additional_accession":[]},"is_claimable":false,"name":"HLA genotyping in the international Type 1 Diabetes Genetics Consortium.","description":"<h4>Background</h4>Although human leukocyte antigen (HLA) DQ and DR loci appear to confer the strongest genetic risk for type 1 diabetes, more detailed information is required for other loci within the HLA region to understand causality and stratify additional risk factors. The Type 1 Diabetes Genetics Consortium (T1DGC) study design included high-resolution genotyping of HLA-A, B, C, DRB1, DQ, and DP loci in all affected sibling pair and trio families, and cases and controls, recruited from four networks worldwide, for analysis with clinical phenotypes and immunological markers.<h4>Purpose</h4>In this article, we present the operational strategy of training, classification, reporting, and quality control of HLA genotyping in four laboratories on three continents over nearly 5 years.<h4>Me","dates":{"release":"2010-01-01T00:00:00Z","publication":"2010","modification":"2025-04-05T09:55:50.944Z","creation":"2019-06-06T22:16:46Z"},"accession":"S-EPMC2917849","cross_references":{"pubmed":["20595243"],"doi":["10.1177/1740774510373494"]}}